IFNG and neoplasm: In a recent clinical trial, patients with stage IIIB, IIIC or IV melanoma received an intratumoral IFNγ injection after they received a vaccine containing 12 class I major histocompatibility complex-restricted melanoma peptides that increased vaccine-induced tumor-infiltrating lymphocytes.